Epidemiologic data assessed the incidence rate of FGFR2 gene fusion or rearrangement in Chinese patients with intrahepatic CCA, including those with heterogeneous FGFR2 partner genes.
The epidemiology of FGFR2 fusions/rearrangements in patients with intrahepatic cholangiocarcinoma (iCCA) in the Chinese population has not been defined. Findings from an observational study (ClinicalTrials.gov Identifier: NCT04256980) that evaluated the incidence of FGFR2 fusions/rearrangements in Chinese patients with iCCA were reported at the 2021 European Society for Medical Oncology Annual Congress.
At data cutoff (October 31, 2020), the study included a total of 728 samples from 728 adult patients with pathologically confirmed iCCA. All samples were tested for FGFR2 fusion or rearrangement; FGFR2 partner genes were assessed in 30 samples with known FGFR2 fusion or rearrangement.
Of the 717 samples that had readout, 6.14% were positive for FGFR2 gene fusion or rearrangement. The incidence rate varied by region, with the highest positive rate (10.5%) found in Southwest China and the lowest positive rate in South China (5%). In the 30 samples tested, a total of 26 different FGFR2 fusion partner genes were identified, 22 (84.6%) of which were unique to individual patients. The most common partner was FGFR2-WAC, which was observed in 10% of the samples.
Findings from this observational study indicate that the incidence rate of FGFR2 gene fusion or rearrangement in Chinese patients with iCCA was 6.14%, which is lower than the rate reported in the global population. The FGFR2 partner genes identified were highly heterogeneous in the Chinese population.
Source: Huang X, Shi G, Zhang T, et al. FGFR2 fusion and/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma. Ann Oncol. 2021;32(suppl_5):S376-S381.
To sign up for our newsletter or print publications, please enter your contact information below.
